ReviewGalen medical journal2025
Evaluation of the Association between Sjögren Syndrome and Thyroid Cancer Risk: A Systematic Review and Meta-analysis : Sjögren Syndrome and Thyroid Cancer Risk.
Review in Galen medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sjögren's syndrome affects the skin, joints, lungs, kidneys, liver, and thyroid. This research was aimed to assess the association of Sjögren's syndrome with the thyroid carcinoma risk. Materials and Methods: The present study was used a systematic review and meta-analysis method. This study searched the databases ProQuest, PubMed, Web of Science, Cochrane, and the search engine Google Scholar until July 7, 2024. The level of significance was considered as P0.05, and all data analyses were done in STATA 14 software. Results: A review of 11 studies revealed that Sjögren's syndrome increased the thyroid carcinoma risk in all patients (OR: 2.08, (95%CI: 1.47, 2.94)), in patients aged 40 to 49 years (OR: 1.43, (95%CI: 1.23, 1.67)), 50 to 59 years (OR: 4.65, (95%CI: 1.87, 11.58)), 60 to 69 years (OR: 1.34, (95%CI: 1.08, 1.66)) and in women ((OR:1.83, (95%CI: 1.35, 2.48). However, there was no significant association between Sjögren's syndrome and thyroid carcinoma risk in men ((OR: 1.49, (95%CI: 0.95, 2.34). Moreover, patients with Sjögren's syndrome who had a follow-up period of = 5 years ((OR: 1.68, (95%CI: 1.10, 2.54) and patients with a follow-up period of 5 years ((OR: 5.77, (95%CI: 1.97, 16.97) were at risk of thyroid cancer. Moreover, the thyroid carcinoma risk was in Europe ((OR: 3.26, (95%CI: 1.24, 8.56) and in Asia ((OR: 1.87, (95%CI: 1.27, 2.74). Primary Sjögren's syndrome also significantly increased the thyroid carcinoma risk ((OR: 2.37, (95%CI: 1.44, 3.90). Conclusion: Sjögren's syndrome increased the thyroid carcinoma risk, and female gender, fifth decade of life, European race, and involvement duration of more than 5 years were the exacerbating factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.